Literature DB >> 17457889

Neuronal PAS domain protein 1 regulates tyrosine hydroxylase level in dopaminergic neurons.

Christina H L Teh1, Chin Chieh Loh, Kevin K Y Lam, Jia Min Loo, Tie Yan, Tit Meng Lim.   

Abstract

Catecholamines (dopamine, norepinephrine, and epinephrine) are all synthesized from a common pathway in which tyrosine hydroxylase (TH) is the rate-limiting enzyme. Dopamine is the main neurotransmitter present in dopaminergic neurons of the ventral midbrain, where dysfunction of these neurons can lead to Parkinson's disease and schizophrenia. Neuronal PAS domain protein 1 (NPAS1) was identified as one of the genes up-regulated during dopaminergic MN9D cell differentiation. We found that there was a corresponding decrease in TH level during MN9D differentiation. Overexpression and siRNA experiments revealed that NPAS1, in concert with ARNT, negatively regulates the expression of TH and that this regulation is mediated by a direct binding of NPAS1 on the TH promoter. Expression studies also confirmed a decrease in TH level in the ventral midbrain during mouse development, concomitant with an increase in NPAS1 level. These results suggest that NPAS1 plays a novel and important role in regulating TH level of dopaminergic neurons in the ventral midbrain during development. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457889     DOI: 10.1002/jnr.21312

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  2 in total

1.  NPAS1-ARNT and NPAS3-ARNT crystal structures implicate the bHLH-PAS family as multi-ligand binding transcription factors.

Authors:  Dalei Wu; Xiaoyu Su; Nalini Potluri; Youngchang Kim; Fraydoon Rastinejad
Journal:  Elife       Date:  2016-10-26       Impact factor: 8.140

2.  Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats.

Authors:  Guiqin Chen; Shuke Nie; Chao Han; Kai Ma; Yan Xu; Zhentao Zhang; Stella M Papa; Xuebing Cao
Journal:  Front Neurosci       Date:  2017-03-09       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.